A new report has found that more than 7,000 cell and gene therapies will progress through the development pipeline, but only 152 contract manufacturing organisations (CMOs) have the capabilities to manufacture them. According to
The report highlights that these bottlenecks will be a major obstacle to large-scale commercial manufacture once more Advanced Therapy Medicinal Products (ATMPs) are approved.
The report says that currently, 79 of these cell and gene therapies are for COVID-19, although the majority of these are in their pre-clinical and discovery phases of development. Two of them are in Phase III, Mesoblast's remestemcel-L and
"With a large number of ATMPs in the drug pipeline greater numbers will be approved. This will require improvements to the production process and the removal of manufacturing bottlenecks to create cost-efficient manufacture at a commercial scale,” said Bradbury.
Report reveals CMOs in
The post Few CMOs equipped to manufacture cell and gene therapies, finds study appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2020. All Rights Reserved., source